The transcription factors of the Myb family are expressed in several tissues and play an important role in cell proliferation, differentiation, and survival. In this study, the expression of A-myb, B-myb, and c-myb was investigated in a group of 64 neuroblastomas at different clinical stages by a sensitive reverse transcription-PCR technique and correlated with patients' survival. All of the myb genes were frequently expressed in neuroblastoma tumors. Interestingly, the expression of B-myb, which was detected in 33 cases, was associated with an increased risk of death (P = 0.027 in a univariate analysis), whereas there was no correlation with A-myb and c-myb expression. In addition, in a multivariate Cox regression analysis that included myb gene expression, MYCN status, age at diagnosis, and tumor staging, MYCN amplification and B-myb expression were independently associated to an increased risk (P < 0.01 and P = 0.015, respectively). In overall survival curves obtained by stratifying the neuroblastoma cases on the basis of MYCN status and B-myb expression, the group of patients without MYCN amplification and positive for B-myb expression had worse survival probability than that without MYCN amplification and nonexpressing B-myb (P < 0.01). In summary, these findings provide the first demonstration that B-myb expression can be a useful prognostic marker in human neuroblastoma. Moreover, B-myb expression has a prognostic value complementary to MYCN amplification and can identify a group of high-risk patients that would not be predicted on the basis of the MYCN status only.
|Pages (from-to)||3365 - 3368|
|Number of pages||4|
|Publication status||Published - 15 Jul 1999|
All Science Journal Classification (ASJC) codes
- Cancer Research